AEGR Related StreetInsider.com Reports
-
Deutsche Bank Takes Aegerion (AEGR) Price Target from $52 to $85
-
Aegerion (AEGR) Pops on Juxtapid Price Increase; Leerink Boosts PT to $65
-
Jefferies More Bullish on Aegerion Pharmaceuticals (AEGR) Following Lipidologists Survey
-
Aegerion Pharmaceuticals, Inc. (AEGR) Tops Q1 EPS by 7c
-
Trading Radar for 04/30: Pfizer (PFE), Cummins (CMI), McGraw-Hill (MHP), DreamWorks (DWA), Sirius (SIRI) Report
-
Aegerion Pharmaceuticals, Inc. (AEGR) Posts Q4 Loss of 86c/Share
-
BofA/Merrill Lynch Starts Aegerion Pharmaceuticals (AEGR) at Buy
-
Lazard Capital Upgrades Aegerion Pharmaceuticals (AEGR) to Buy
-
Notable 52-Week Highs and Lows of the Day 01/11: (F) (AXP) (GGC) High; (BV) Low
-
StreetInsider.com Pre-Open Movers 01/11: (INFY) (DNDN) (BBY) Higher; (ARQL) (KBR) (JCP) Lower (more...)
-
Aegerion Pharma (AEGR) Prices 2.7M Offering at $26.64/Share
-
Streetinsider.com After-Hours Movers 1/10: (UPIP) (AEGR) Higher; (KBR) (XRTX) (AXP) Lower (more...)
-
Aegerion Pharmaceuticals (AEGR) Plans Common Stock Offering
-
Aegerion Pharma (AEGR) Updates on JUXTAPID, Outlook for FY13
-
Janney Montgomery Scott Starts Aegerion Pharmaceuticals (AEGR) at Buy
-
Jefferies Boosts Target on Aegerion (AEGR) to $29 Ahead of Juxtapid Commercialization
-
Analyst Bullish as Aegerion (AEGR) Drug Approved with Broad Label
-
StreetInsider.com Pre-Open Movers 12/24: (HLF) (NUS) (FB) Higher; (ALXA) (HOV) (AEGR) Lower (more...)
-
Aegerion Pharmaceuticals (AEGR) Halted on FDA Approval News
-
Aegerion (AEGR) Receives FDA Approval for JUXTAPID Caps
-
Notable Analyst Rating Changes 12/21: (ACMP) (CIB) (EAT) Upgraded; (RIMM) (GG) (HLF) Downgraded
-
Cowen Starts Aegerion Pharmaceuticals (AEGR) at Outperform
-
Aegerion Pharma (AEGR) Receives EPO Patent for Hyperlipidemia Treatment Method
-
(AEGR) (GEVA) (MACK) (SUPN) (XOMA) (ZGNX) to be Added to NASDAQ Biotechnology Index (IBB)
-
Aegerion Pharma (AEGR) Posts Q3 Loss of 59c/Share, Misses Views
-
Trading Radar for 11/07: Qualcomm (QCOM), Leap Wireless (LEAP), Activision (ATVI), SodaStream (SODA), Monster Beverage (MNST) Report
-
Jefferies Boosts Price Target on Aegerion (AEGR) after Positive FDA Panel
-
Unusual 11 Mid-Day Movers 10/18: (BWEN) (OEH) (GIVN) Higher; (ALGN) (MNKD) (MLNX) Lower
-
Needham & Company Raises Aegerion Pharmaceuticals (AEGR) Price Target to $30
-
Pre-Open Movers 10/18: (GIVN) (SVU) (AEGR) Higher; (ALGN) (MLNX) (IMUC) Lower (more...)
-
Aegerion (AEGR) Wins FDA Approval of Lomitapide in Lowering Cholesterol with HoFH Patients
-
Aegerion (AEGR) Trading Halted Ahead of Lomitapide FDA Committee Meeting
-
Pre-Open Movers 10/15: (CLWR) (EDU) (AEGR) Higher; (DCTH) (CNX) (ELN) Lower (more...)
-
Aegerion (AEGR) Lomitapide Briefing Docs Posted; FDA Panel Says More Patients Needed to Rule Out Cancer Risk
-
Unusual 11 Mid-Day Movers 10/12: (NINE) (GLUU) (NPSP) Higher; (AEZS) (OCZ) (TZOO) Lower
-
Capstone Investments Starts Aegerion Pharmaceuticals (AEGR) at Buy
-
FMR LLC Raises Stake in Aegerion Pharmaceuticals (AEGR) to 10.36%
-
JPMorgan Starts Aegerion Pharmaceuticals (AEGR) at Overweight
-
Aegerion Pharmaceuticals (AEGR) Announces Date of Advisory Committee Review for Lomitapide NDA
-
Aegerion Pharmaceuticals, Inc. (AEGR) Posts Q2 Loss of 63c/Share
-
ThinkEquity Starts Aegerion Pharmaceuticals (AEGR) at Buy
-
Needham & Company Reiterates a 'Buy' on Aegerion Pharmaceuticals (AEGR); Profitability By 2014
-
Unusual 11 Mid-Day Movers 06/14: (NBG) (GMO) (JASO) Higher; (NOK) (EGT) (LSCC) Lower
-
Morning Movers 06/14: (NBG) (JASO) (GMO) (IGT) Higher; (LSCC) (NOK) (AEGR) Lower
-
Pre-Open Losers 6/14: (NOK) (CS) (AEGR) (more...)
-
Aegerion Pharma (AEGR) Hit Early, Prices 3.7M Offeering at 10.8% Discount
-
Aegerion Pharma (AEGR) Prices 3.4M Shares at $14.75/Share
-
After-Hours Movers 06/13: (RPTP) (CTRP) (SVU) Higher; (AEGR) Lower
-
Aegerion Pharma (AEGR) Announces Common Offering
-
Canaccord Genuity maintains a 'Buy' on Aegerion Pharmaceuticals (AEGR); Time For Some Answers
Back to AEGR Stock Lookup
